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Abstract 
Background: The efficacy of dexamethasone plus palonosetron for postoperative nausea and vomiting 
(PONV) prophylaxis is not firmly established. This randomized, double-blind, controlled study evaluated 
whether the combination was superior to palonosetron alone in preventing PONV in patients receiving 
intravenous patient-controlled analgesia (IV-PCA) after upper extremity surgery.  
Methods: A total of 202 patients undergoing upper extremity surgery were randomly assigned to group 
P (palonosetron alone) or group PD (palonosetron plus dexamethasone). Group P patients received 
palonosetron 0.075 mg and normal saline 1.6 mL; group PD patients received palonosetron 0.075 mg and 
dexamethasone 8 mg. In both groups, palonosetron was added to the IV-PCA opioid infusion, which was 
continued for 48 h postoperatively. Incidence and severity of nausea, incidence of vomiting, rescue 
antiemetic requirements, pain intensity, and rescue analgesic requirements were evaluated for 72 h 
postoperatively. Quality of recovery was assessed using the quality of recovery-15 (QoR-15) 
questionnaire. 
Results: The incidence of PONV was significantly lower in group PD than in group P at 0-48 h 
postoperatively (61.5% vs 77.1%; p = 0.019). Severity of nausea at 0-6 h postoperatively was significantly 
less in group PD compared with group P (none/mild/moderate/severe: 49/22/15/10 vs. 36/16/25/19, p = 
0.008). The incidence of vomiting and rescue antiemetic requirements were similar between groups. Pain 
intensity was significantly less in group PD than in group P at 0-48 h and 48-72 h postoperatively. Global 
QoR-15 was similar 24 h postoperatively between groups. 
Conclusions: Dexamethasone–palonosetron combination therapy reduced PONV incidence and 
postoperative pain in patients receiving opioid-based analgesia after upper extremity surgery. 
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Background 
Postoperative nausea and vomiting (PONV) is 
one of the most common and distressing 
complications after surgery under general anesthesia. 
PONV may cause dehydration, electrolyte imbalance, 
aspiration of gastric contents, would dehiscence, 
bleeding, and delayed hospital discharge [1]. Despite 
the development of new antiemetics, the incidence of 
PONV still ranges from 10% to 80%, depending on the 
presence of risk factors [2]. Factors associated with an 








nonsmoking, postoperative opioid use, and history of 
motion sickness or PONV [2]. Opioid-based 
intravenous patient-controlled analgesia (IV-PCA), 
which is widely used for postoperative pain control, is 
associated with a high incidence of PONV [3]. 
Accordingly, multimodal strategies have been 
advocated to reduce the incidence of PONV in 
high-risk patients, including risk stratification and 
modification, and combination therapy of antiemetics 
with different sites of action [4].  
5-hydroxytryptamine3 (5-HT3) receptor 
antagonists are widely used for preventing PONV. 
They selectively bind to 5-HT3 receptors in 
chemoreceptors within the brain and visceral vagal 
afferents [5]. Palonosetron, a second-generation 5-HT3 
receptor antagonist, has a higher affinity for 5-HT3 
receptors and longer half-life (>40 h) than other 5-HT3 
antagonists because of its unique structure [6, 7]. 
Glucocorticoids exert antiemetic properties by 
antagonizing prostaglandins or releasing endorphins 
[8, 9]. They can also potentiate other antiemetics by 
sensitizing pharmacologic receptors. Given these 
pharmacologic profiles, combining palonosetron and 
dexamethasone provides better prevention against 
chemotherapy-induced nausea and vomiting than 
palonosetron alone [10]. However, the few trials 
evaluating palonosetron–dexamethasone combina-
tion therapy for PONV prophylaxis produced 
conflicting results [11-13]. The discrepancies may be 
attributable to different observation periods and 
relatively small sample sizes, which increase the 
influence of interindividual pharmacokinetic and 
pharmacodynamic differences.  
Palonosetron–dexamethasone combination ther-
apy has not been heretofore compared to 
palonosetron monotherapy for preventing PONV 
related to opioid-based IV-PCA. Therefore, we 
conducted a prospective, randomized, double-blind 
study to evaluate whether combining the combination 
would be superior to palonosetron alone for 
preventing PONV in patients receiving IV-PCA 
opioids after upper extremity surgery.  
Methods  
Study design and patient selection  
This randomized controlled trial was approved 
by the institutional ethics review committee of 
Severance Hospital, Korea (No.4-2015-0232) and 
registered at ClinicalTrials.gov (NCT02744508). A 
total of 202 patients were enrolled in this study 
between July 2015 and March 2017 at Severance 
Hospital. Patient inclusion criteria were as follows: 
age 20–65 years, undergoing elective upper extremity 
surgery under general anesthesia, American Society 
of Anesthesiologists’ physical status class I-II, and use 
of IV-PCA for postoperative analgesia. Patients were 
excluded if they had one or more of the following: use 
of antiemetic medication within 24 h of surgery, 
glucocorticoids within 24 h before or after surgery, 
chronic opioid use, presence of renal dysfunction 
(serum creatinine >1.6 mg/dL) or hepatic 
insufficiency (liver enzymes more than twice the 
upper limit of normal), allergy to 5-HT3 receptor 
antagonists, obesity (body mass index ≥35 kg/m2), 
pregnant, and borderline or definite QTc prolongation 
(>430 ms for males, >450 ms for females). Written 
informed consent was obtained from all patients 
before enrollment. 
 The day before surgery, the principal 
investigator (Y.S.C.) randomly allocated the patients 
to either the palonosetron group (group P) or 
palonosetron plus dexamethasone group (group PD), 
using computer-generated random-number codes. 
The other investigators, anesthesiologists responsible 
for the patients’ care, surgeons, and patients were 
blinded to the group assignments during the entire 
study period.  
Perioperative management  
No premedication was administered. On arrival 
in the operating room, standard anesthetic monitors 
were applied. Anesthesia was induced with 
remifentanil 1.0 μg/kg and propofol 1.5 mg/kg, and 
orotracheal intubation was facilitated with 
rocuronium 0.6 mg/kg. According to the allocated 
group, dexamethasone 8 mg or normal saline 1.6 mL 
was injected immediately after induction of 
anesthesia. The study drugs were prepared in 
identical syringes by nurses not involved in the study. 
Anesthesia was maintained with 0.1-0.2 μg/kg/min 
remifentanil intravenous (IV) infusion and 1.5%-2% 
sevoflurane in 50% oxygen/air. Approximately 30 
min before the end of surgery, all patients received IV 
palonosetron 0.075 mg. Fifteen minutes before the end 
of surgery, the remifentanil infusion was stopped, and 
IV fentanyl 1 µg/kg was administered to reduce 
postoperative pain. Concurrently, IV-PCA was 
commenced, which consisted of fentanyl 20 μg/kg 
plus palonosetron 0.075 mg (total volume including 
saline: 100 mL), delivered as a 2 mL/h background 
infusion and 0.5-ml demand doses with a 15-min 
lockout period. This was continued for 48 h after 
surgery. Upon completion of surgery, neuromuscular 
blockade was antagonized with glycopyrrolate (0.2 
mg) and neostigmine (50 μg/kg).  
Assessments  
Primary study endpoint was to compare the 
overall incidence of PONV between two groups for 
the first 48 h after surgery during hospitalization. 
Secondary endpoints were the incidence of 




postdischarge nausea and vomiting (PDNV), 
incidence and severity of nausea, incidence of 
vomiting, rescue antiemetic requirements, pain 
intensity, and rescue analgesic requirements. 
Outcome variables were assessed at 0-6, 6-24, 24-48, 
and 48-72 h postoperatively. Nausea intensity was 
graded on an 11-point verbal numeric rating scale 
(VNRS), from 0 = no nausea to 10 = worst possible 
nausea. Nausea severity was classified according to 
VNRS scores: mild (1–3), moderate (4–6), and severe 
(7–10). IV metoclopramide 10 mg was administered 
when the nausea VNRS was ≥4 or the patient 
requested an antiemetic. In case of severe persistent 
nausea after administering metoclopramide, or by 
patient request, IV-PCA was stopped for 2 h. 
Vomiting was defined as forceful expulsion of gastric 
contents (true vomiting) or vomiting-like action 
without gastric contents (retching). Pain was 
evaluated using an 11-point VNRS, from 0 = no pain 
to 10 = worst imaginable pain. IV tramadol 50 mg was 
given for a pain VNRS ≥4 or upon patient request. The 
quality of recovery (QoR)-15 questionnaire was used 
to evaluate recovery from anesthesia [14]. The QoR-15 
was administered the day before surgery and 24 h 
postoperatively. If patients were discharged home 
before 72 h postoperatively, we contacted them by 
telephone to collect data regarding PDNV. Pain 
medications at discharge included oral tramadol 37.5 
mg and acetaminophen 325 mg twice daily for 5 days.  
Statistical analysis 
Based on the 67% incidence of PONV with 
palonosetron reported previously [3], we determined 
that 96 patients in each group would be necessary to 
detect a 20% decrease in the incidence of PONV with a 
power of 80% and a type I error of 0.05. To account for 
a potential 5% dropout rate, we enrolled 202 patients. 
Data are presented as mean ± standard deviation or 
median (interquartile range) for continuous variables 
or number (percentage) for categorical variables. Data 
were analyzed with the independent t-test or 
Mann-Whitney U test for continuous variables and 
chi-square or Fisher’s exact test for categorical 
variables. P-values < 0.05 were considered statistically 
significant. Statistical analyses were performed with 
SPSS 23.0 (SPSS Inc., Chicago, IL, USA).  
Results 
Among the 254 patients assessed for eligibility, 
202 were enrolled in this study. After allocation, eight 
patients refused IV-PCA on the day of surgery or 
withdrew their consent; during follow-up, IV-PCA 
pumps were discontinued in two patients in group P 
following attempt of temporary interruption; data 
from the 192 remaining patients were finally analyzed 
(Fig. 1). Patient characteristics (including Apfel’s risk 
scores [2]), and duration of surgery and anesthesia 
were comparable between two groups (Table 1). 
 
 
Figure 1. Flow diagram of the study 





Table 1. Patient characteristics and duration of surgery and 
anesthesia  
 Group P (n = 96) Group PD (n = 96) p value  
Age (y) 45.5 ± 13.7 44.1 ± 13.9 0.491 
Sex (male/female) 51/45 45/51 0.386 
Height (cm) 166.1 ± 10.1 164.9 ± 9.32 0.418 
Weight (kg) 66.5 ± 12.3 65.0 ± ±13.3 0.438 
Body mass index (kg/m2) 24.0 ± 3.1 23.8 ± 3.6 0.703 
Apfel risk score *   0.779 
 1 21 (21.9%) 20 (20.8%)  
 2 44 (45.8%) 43 (44.8%)  
 3 29 (30.2%) 31 (32.3%)  
 4 2 (2.1%) 2 (2.1%)  
Duration of surgery (min) 80.8 ± 47.8 76.8 ± 40.1 0.533 
Duration of anesthesia (min) 123.4 ± 53.3 118.4 ± 49.6 0.500 
Type of surgery   0.604 
 Bone surgery 52 (54.2%) 43 (44.8%)  
 Soft tissue surgery 26 (27.1%) 30 (31.3%)  
 Arthroplasty 3 (3.1%) 3 (3.1%)  
 Arthroscopy 15 (15.6%) 20 (20.8%)  
Intraoperative crystalloid (mL) 455 ± 193 416 ± 209 0.183 
Data are presented as mean ± standard deviation, number of patients, or number of 
patients (percentage). 
Group P received palonosetron; Group PD received palonosetron plus 
dexamethasone.  
* Based on the reference [2]. 
 
Table 2. Incidence of nausea, vomiting, and rescue antiemetic 
requirements during hospital stay  
 Group P (n = 96) Group PD (n = 96) p value 
0-6 h after surgery 
 Nausea 60 (62.5%) 47 (49.0%) 0.059 
 Vomiting 10 (10.4%) 8 (8.3%) 0.620 
 PONV 61 (63.5 %) 47 (49.0 %)  0.042* 
 Rescue antiemetics 19 (19.8%) 20 (20.8%) 0.858 
6-24 h after surgery    
 Nausea 62 (64.6%) 52 (54.2%) 0.142 
 Vomiting 11 (11.5%) 11 (11.5%) 1.000 
 PONV 62 (64.6 %) 52 (54.2 %) 0.142 
 Rescue antiemetics 6 (6.3%) 11 (11.5%) 0.204 
24-48 h after surgery    
 Nausea 42 (43.8%) 37 (38.5%) 0.463 
 Vomiting 3 (3.1%) 5 (5.2%) 0.721 
 PONV 42 (43.8 %) 37 (38.5 %) 0.463 
 Rescue antiemetics 2 (2.1%) 1 (1.0%) 1.000 
0-48 h after surgery    
 Nausea 74 (77.1%) 59 (61.5%) 0.019* 
 Vomiting 19 (19.8%) 16 (16.7%) 0.575 
 PONV 74 (77.1 %) 59 (61.5 %)  0.019* 
 Rescue antiemetics 24 (25.0%) 25 (26.0%) 0.869 
Data are presented as number of patients (percentage). 
PONV, postoperative nausea and vomiting 
Group P received palonosetron; Group PD received palonosetron plus 
dexamethasone.  
* p <0.05  
 
Table 3. Incidence of nausea and vomiting and intensity of pain 
after discharge to home  
 Group P (n = 84) Group PD (n = 87) p value 
48-72 h after surgery     
 Nausea 33 (39.3%) 28 (32.3%) 0.332 
 Vomiting 0 (0.0 %) 2 (2.3%) 0.497 
 PDNV 33 (39.3 %) 28 (32.2 %) 0.332 
 Median VNRS pain scores 3.0 (1.1-4.0) 1.0 (0.0-3.0) 0.001* 
Data are presented as number of patients (percentage) or median (interquartile 
range). 
PDNV, postdischarge nausea and vomiting, VNRS, verbal numeric rating scale 
Group P received palonosetron; Group PD received palonosetron plus 
dexamethasone.  
* p <0.05  
Table 4. Pain intensity and rescue analgesics during hospital stay 
 Group P (n = 
96) 
Group PD (n = 96) p value 
Median VNRS pain scores 
 0-6 h after surgery 5.0 (4.0-7.0)  4.0 (3.0-6.0) <0.001* 
 6-24 h after surgery 5.0 (3.0-6.0) 3.0 (1.0-4.0) <0.001* 
 24-48 h after surgery 3.0 (2.0-5.0) 2.0 (1.0-4.0) 0.001* 
Patients requiring rescue analgesics 
 0-6 h after surgery 40 (41.7%) 28 (29.2%) 0.070 
 6-24 h after surgery 16 (16.7%) 15 (15.6%) 0.845 
 24-48 h after surgery 2 (2.1%) 3 (3.1%) 1.000 
Total amount of tramadol (mg) 
 0-48 h after surgery 30.0 ± 36.4 26.8 ± 49.4 0.618 
Data are presented as median (interquartile range), number of patients 
(percentage), and mean ± standard deviation.  
VNRS, verbal numeric rating scale 
Group P received palonosetron; Group PD received palonosetron plus 
dexamethasone.  
* p <0.05  
 
The incidence of PONV was significantly lower 
in group PD than in group P at 0-6 h (49.0% vs 63.5%, 
p < 0.05) and 0-48 h postoperatively (61.5% vs 77.1%, p 
< 0.05), but not at 6-24 h (54.2% vs 64.6%) and 24-48 h 
(38.5% vs 43.8%) (Table 2). Among the 192 patients, 
171 were discharged around 48 h postoperatively and 
were interviewed by telephone the next day; 21 were 
discharged 72 h after surgery. The incidence of PDNV 
was similar between groups at 48-72 h 
postoperatively (Table 3). The incidence of nausea 
was lower in group PD than in group P at 0-48 h 
postoperatively (61.5% vs 77.1%, p = 0.019), but not at 
48-72 h. The incidence of vomiting and rescue 
antiemetic requirements were similar between groups 
throughout the observation period. Nausea severity 
was graded as none, mild, moderate, and severe in 49, 
22, 15, and 10 patients, respectively, in group PD; and 
as 36, 16, 25, and 19 patients, respectively, in group P 
(p = 0.008) (Fig. 2). Nausea severity was similar 
between groups during at 6-24 h, 24-48 h, and 48-72 h 
postoperatively. The need to temporarily discontinue 
IV-PCA due to PONV was similar between groups 
(four patients in group P vs. five in group PD). 
Pain intensity (VNRS scores) was significantly 
lower in group PD than in group P at 0-48 h and 48-72 
h postoperatively (Table 4). The number of patients 
requiring rescue analgesics and total amount of rescue 
analgesic (tramadol) was similar between groups at 
0-48 h (Table 4). 
Preoperative global QoR-15 scores were similar 
between groups (group P, 132.0±18.7 vs group PD, 
134.4±15.8, p = 0.345). Postoperative global QoR-15 
scores were comparable between groups, but four 
questions were significantly higher in group PD than 
in group P: “getting support from hospital doctors 
and nurses” (9.4±1.5 vs. 8.4±2.5, p = 0.001); “having a 
feeling of general well-being” (8.5±2.0 vs. 7.7±2.9, p = 
0.033); “moderate pain” (5.9±3.2 vs. 4.9±2.9, p = 0.040); 
and “severe pain” (7.6±3.1 vs. 6.3±3.1 vs p = 0.007) 
(Table 5).  




Table 5. Postoperative quality of recovery (QoR)-15 scores  
QoR-15 Item Group P (n = 
96) 
Group PD (n = 
96) 
p value 
1. Able to breathe easy 9.4 ± 1.4 9.3 ± 1.2 0.621 
2. Been able to enjoy food 6.8 ± 3.8 7.3 ± 3.3 0.383 
3. Feeling rested 6.3 ± 3.2 6.5 ± 2.7 0.698 
4. Have had a good sleep 6.7 ± 3.4 6.1 ± 3.3 0.234 
5. Able to look after personal toilet and 
hygiene unaided 
6.6 ± 3.3 6.7 ± 3.3 0.780 
6. Able to communicate with family or 
friends 
9.3 ± 1.9 9.7 ± 1.0 0.127 
7. Getting support from hospital doctors 
and nurses 
8.4 ± 2.5 9.4 ± 1.5 0.001* 
8. Able to return to work or usual home 
activities 
7.0 ± 3.6 6.4 ± 3.4 0.252 
9. Feeling comfortable and in control 8.5 ± 2.4 8.5 ± 2.1 0.949 
10. Having a feeling of general well-being 7.7 ± 2.9 8.5 ± 2.0 0.033* 
11. Moderate pain  4.9 ± 2.9 5.9 ± 3.2 0.040* 
12. Severe pain 6.3 ± 3.1 7.6 ± 3.1 0.007* 
13. Nausea or vomiting 6.8 ± 3.2 7.0 ± 3.5 0.670 
14. Feeling worried or anxious 8.2 ± 2.7 8.1 ± 2.7 0.894 
15. Feeling sad or depressed 8.3 ± 3.0 8.6 ± 2.7 0.467 
Total 111.5 ± 27.3 115.6 ± 24.3 0.298 
Data are presented as mean ± standard deviation. QoR, quality of recovery. 
In QoR-15, the first ten questionnaires showed ratings from 0 (none of the time) to 
10 (all of the time) and the last five questionnaires reversely showed ratings from 10 
(all of the time) to 0 (none of the time). 
Group P received palonosetron; Group PD received palonosetron plus 
dexamethasone.  
* p <0.05  
 
The most common 5-HT3 antagonist-related 
adverse effects were dizziness (group P, 20; PD, 17) 
and headache (group P, 19; PD, 13); the incidence of 
these effects was similar between groups throughout 
the study. No patient developed delayed wound 
healing, infection, or glucose intolerance. The 
duration of postoperative hospital stay was similar in 
both groups.  
Discussion 
In this prospective, randomized, double-blind 
trial, we demonstrated that combining dexametha-
sone 8 mg with palonosetron 0.075 mg was superior to 
palonosetron 0.075 mg alone in reducing the 
incidence of PONV related to opioid-based IV-PCA 
during the first 48 h after upper extremity surgery. 
The combination also conferred superior analgesia, 
significantly reducing pain scores throughout the 72-h 
postoperative period. It likewise produced significant 
benefits for certain aspects of quality of recovery after 
surgery: better perception of receiving support from 
hospital personnel, better general well-being, and less 
pain.  
The etiology of PONV is multifactorial, with 
several established risk factors that include female 
gender, non-smoker status, history of PONV or 
motion sickness, use of perioperative opioids, use of 
volatile anesthetics, duration of anesthesia, duration 
of surgery, and type of surgery [2]. Postoperative pain 
management using opioid-based IV-PCA often 
produces PONV, which is the most common reason 
for patient dissatisfaction with this analgesic strategy. 
Accordingly, when opioid-based IV-PCA is planned, 
clinicians often initiate prophylactic antiemetic 
treatment. Current PONV guidelines recommend 
combined antiemetic therapies targeting different 
receptors in patients with a moderate to high risk for 
PONV [4]. In this study, PONV risk factors were 
similar between groups; thus, the difference in 
incidence of PONV between groups is attributed to 
the additive or synergistic effect of adding 
dexamethasone to palonosetron.  
Dexamethasone plus a 5-HT3 receptor antagonist 
has been previously reported to reduce the incidence 
of PONV compared with 5-HT3 receptor antagonist 
alone [9, 15]. Although the precise mechanism of 
dexamethasone’s antiemetic effect is unclear, leading 
 
Figure 2. Distribution (percentage) of nausea severity according to a four-point rating scale (none, mild, moderate, or severe). 
 




theories include prostaglandin antagonism and 
endorphin release [8, 9]. Furthermore, dexamethasone 
may inhibit the synthesis and release of 5-HT by 
depleting tryptophan (a 5-HT precursor) or it may 
prevent activation of 5-HT receptors in the 
gastrointestinal tract through its anti-inflammatory 
properties [16, 17]. Palonosetron exhibits allosteric 
interactions and triggers receptor internalization; this 
produces high receptor affinity, making palonosetron 
the most potent available 5-HT3 antagonist, with a 
40-h elimination half-life [6, 18]. A recent 
meta-analysis showed that palonosetron provided 
better prophylaxis of early (0-6 h) and late (6-24 h) 
postoperative nausea, as well as late (6-24 h) 
postoperative vomiting, compared with ondansetron 
[19]. In another meta-analysis, palonosetron was more 
effective in preventing postoperative vomiting than 
ramosetron during the delayed period (24-48 h) and in 
females and after laparoscopic surgery [20]. This 
delayed period is especially important in patients 
receiving opioid-based IV-PCA because continuous 
infusion of opioids could cumulatively influence 
PONV in a dose-related [21]. Although we found that 
palonosetron–dexamethasone reduced the incidence 
of PONV and the incidence and severity of nausea 
during the 48-h postoperative period compared with 
palonosetron alone, it did not affect vomiting. As 
palonosetron has more antiemetic than antinauseant 
efficacy, the main effect of dexamethasone may have 
been preventing nausea [20, 22]. Furthermore, adding 
palonosetron to the IV-PCA in all patients potentially 
influenced our results. Contrary to our expectation, 
the palonosetron–dexamethasone combination did 
not reduce the incidence of PDNV at 48-72 h. Since the 
duration of single dexamethasone for prevention of 
PONV lasts for about 24 hours, the comparable 
incidence of PDNV at 48-72 h may be explained by 
prolonged (>40 h) duration of action of palonosetron 
itself [23]. Our overall incidence of PDNV was 36%, 
which is similar to the incidence previously reported 
[24].  
 In this study, incidence of PONV at 0-24 h was 
still higher than that of previous studies [12, 13]. The 
use of opioid-based IV-PCA might explain this result. 
In our study, all patients were at least with Apfel risk 
score 1 due to IV-PCA use, and more than half of them 
were with Apfel risk scores 2 and 3. High background 
infusion dosage of fentanyl (0.4 μg/kg/h) of IV-PCA 
in our study might also increase the incidence of 
PONV [25]. Although there is no definite dose of 
opioid that increases the risk of PONV, it is known 
that a higher dose of opioid tends to increase the risk 
of PONV [21]. 
Only a few previous studies evaluated the 
dexamethasone–palonosetron combination for 
preventing PONV. Our results are consistent with 
those of a previous study comparing palonosetron 
0.075 mg plus dexamethasone 8 mg with palonosetron 
alone, in which the complete response rate (no 
vomiting, no antiemetic rescue medications) and 
PONV were superior with combination therapy 
during 24 h postoperatively in 84 patients undergoing 
laparoscopic cholecystectomy [12]. In a study 
comparing palonosetron 0.075 mg plus 
dexamethasone 8 mg with palonosetron monotherapy 
in 118 patients undergoing outpatient laparoscopy, 
the incidence of PONV at 72 h was similar and 
relatively low (31% and 32%) in both groups [13]. In 
another study involving 84 females undergoing 
various types of surgery, the complete response rate 
and incidence of PONV were similar for palonosetron 
0.075 mg plus dexamethasone 4 mg and palonosetron 
monotherapy [11]. However, this study used a 
suboptimal dexamethasone dose. Although 
dexamethasone 2.5–5 mg is the minimum effective 
dose for PONV prophylaxis, current literature 
suggests that the optimal dose is 8 mg [8, 15].  
In our study, administering dexamethasone 8 
mg before surgical incision reduced pain scores 
during the 72-h postoperative period. A recent 
meta-analysis showed that a single perioperative dose 
of dexamethasone (1.25–20 mg) reduced 
postoperative pain, opioid consumption, and need for 
rescue analgesics, and prolonged the time to first 
analgesic dose [26]. The onset of action of 
dexamethasone is approximately 1–2 h, representing 
the time for diffusion across cell membranes and 
alteration of gene transcription [27]. Thus, 
administering glucocorticoids approximately 1 h 
before surgical trauma may be important for 
minimizing pain and inflammation [8].  
Generally, palonosetron is recommended to be 
administered at anesthetic induction due to its slow 
onset of action [4]. In our study, palonosetron was 
administered approximately 30 min before the end of 
surgery considering its time-to-peak concentration of 
2-9 minutes to maximize the duration of palonosetron 
after surgery [28]. Thereby, the incidence of PONV in 
0-6 h after surgery in the palonosetron group might be 
affected by the timing of palonosetron administration, 
even though it is administered at the same time point 
in both groups. However, previous studies have 
shown that palonosetron significantly reduces PONV, 
regardless of when it is administered [29, 30]. In 
addition, one study showed that there was no 
significant effect on prevention of PONV according to 
the timing of palonosetron administration [28]. 
Therefore, further research is required to investigate 
the proper timing of palonosetron for PONV 
prevention. 




The importance of evaluating recovery from the 
patients’ perspective, considering their emotions or 
feelings, has been previously established [14, 31, 32]. 
QOR-15 evaluates postoperative recovery in multiple 
dimensions, including pain, physical comfort, 
physical independence, psychological support, and 
emotional state. It is valid, reliable, acceptable, and 
quickly completed [14]. In this study, patients 
receiving combination therapy scored higher for 
questions about pain and mental well-being. This is 
consistent with the results of a previous study 
showing that 8 mg dexamethasone improved patient 
recovery and satisfaction [31]. Enhanced feelings of 
well-being and of being supported might be 
attributed to dexamethasone’s effects on mood, which 
may be due to direct effects on the central nervous 
system or indirect anti-inflammatory effects [33]. 
Reducing nausea and improving pain likely also 
improved patient satisfaction and recovery. 
There are a few limitations in our study. First, 
this study was done without the placebo for ethical 
reasons since we evaluated patients with a moderate 
to high risk for PONV. Second, most patients were 
discharged home around 48 h, requiring assessment 
by telephone 48-72 h postoperatively. However, this 
allowed us to study the effects of prophylaxis in two 
settings: inpatients and post-discharge outpatients. 
Third, the consumption of IV-PCA used was not 
measured in this study. The lower incidence of PONV 
in group PD might be associated with less IV-PCA 
use, related to analgesic effect of dexamethasone. To 
delineate this possibility, bolus-only mode of IV-PCA 
might be more helpful. 
Conclusions 
The combination of dexamethasone and 
palonosetron was more effective than palonosetron 
alone in reducing the incidence of PONV in patients 
receiving opioid-based analgesia during the first 48 h 
after upper extremity surgery. The combination also 
reduced the intensity of postoperative pain and 
improved certain aspects of the quality of recovery. 
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